KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Current Taxes (2017 - 2025)

Sarepta Therapeutics (SRPT) has 7 years of Current Taxes data on record, last reported at $9.1 million in Q3 2025.

  • For Q3 2025, Current Taxes changed N/A year-over-year to $9.1 million; the TTM value through Sep 2025 reached $9.1 million, changed N/A, while the annual FY2024 figure was $17.4 million, 26.33% up from the prior year.
  • Current Taxes reached $9.1 million in Q3 2025 per SRPT's latest filing, down from $18.7 million in the prior quarter.
  • Across five years, Current Taxes topped out at $79.9 million in Q1 2025 and bottomed at $216000.0 in Q4 2021.
  • Average Current Taxes over 5 years is $19.6 million, with a median of $16.7 million recorded in 2023.
  • Peak YoY movement for Current Taxes: soared 5696.76% in 2022, then rose 9.94% in 2023.
  • A 5-year view of Current Taxes shows it stood at $216000.0 in 2021, then skyrocketed by 5696.76% to $12.5 million in 2022, then grew by 9.94% to $13.8 million in 2023, then increased by 26.33% to $17.4 million in 2024, then plummeted by 47.73% to $9.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Taxes were $9.1 million in Q3 2025, $18.7 million in Q2 2025, and $79.9 million in Q1 2025.